V. I. Surinova

V. I. Surinova

Auto-generated profile, based on publicly available information

V. I. Surinova

A.Tsyb Medical Radiological Research Centre – Branch of the National Medical Research Radiological Centre Obninsk, Russian Federation

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2026 in South Russian Journal of Cancer
Verified
Journal Article
Open access
PDF file
OSOlga V. Soldatova
Olga V. Soldatova
MFMarina Filimonova
Marina Filimonova
VSV. I. Surinova
V. I. Surinova
ASAnna Shitova
Anna Shitova
Vitaly RybachukVitaly Rybachuk
Vitaly Rybachuk
AFA.S. Filimonov
A.S. Filimonov
The Laboratory of Radiation Pharmacology has previously developed water-­soluble dialkylaminoalkyl esters of indole‑3‑carboxylic acid, which demonstrated high immunomodulatory, antiviral, and antitumor activity. Based on these established properties, we aimed to enhance their antitumor effect by incorporating cytotoxic alkylating bromo- or bis(2‑chloroethyl)amino substituents into their molecular structure. Compounds T1167 and T1089 were successfully synthesized. Purpose of the study . To investigate the antitumor and antimetastatic properties of bromo-, bis(2‑chloroethyl)amino-substituted derivatives of N-methyl ethyl esters of indole‑3‑carboxylic acid (T1089 and T1167). Materials and methods . The study was performed on 65 mice with subcutaneously transplanted lymphogenously metastasizing sarcoma S‑37 (9 × 10 5 cells/mouse). Compounds were administered intraperitoneally: T1089 at 40 mg/kg, T1167 at 30 mg/kg. Antitumor efficacy was assessed by primary tumor growth dynamics, morphometric and histological parameters. Results . The studied compounds inhibited primary tumor growth of sarcoma S‑37 (TGI for T1089–22,4 %, for T1167–30,5 %), increased dystrophic and necrotic changes in tumors (T1089 – by 36 %, T1167 – by 55 %), reduced mitotic index by 2‑fold, and exhibited antimetastatic activity, decreasing metastatic areas in inguinal lymph nodes (day 10: T1089 – by 76 %, T1167 – by 89 %) and iliac lymph nodes (day 10: T1089 – by 28,7 %, T1167 – by 60,8 %; day 16: T1089 – by 53,3 %, T1167 – by 45,6 %). Conclusion . Antitumor and antimetastatic activity of compounds T1089 and T1167 was demonstrated in the sarcoma S‑37 model. The obtained data indicate the promise of compounds combining alkylating cytotoxicity with the immunomodulatory potential inherent to this class. Further research will involve preclinical development including safety assessment, expansion of the range of tumor models studied, and detailed investigation of the mechanisms of action.


10 January 2026 in Radiatsionnaya Gygiena = Radiation Hygiene
Verified
Journal Article
Open access
PDF file
OSOlga V. Soldatova
Olga V. Soldatova
MFMarina Filimonova
Marina Filimonova
VSV. I. Surinova
V. I. Surinova
ASAnna Shitova
Anna Shitova
KNKirill Nikolaev
Kirill Nikolaev
AFA.S. Filimonov
A.S. Filimonov
Despite significant progress in the field of chemoradiation antitumor therapy, the introduction of new pharmacological agents and radiation response modifiers aimed at increasing the therapeutic index of radiation therapy remains one of the priority tasks of experimental oncology and radiobiology. Objective of the study is evaluation of the antitumor effects of the combined use of ionizing radiation (electrons, protons) and a new derivative of indole-3-carboxylic acid – 1-methyl-2-bromomethyl-3-ethoxycarbonyl-5-methoxy-6-bromindole. Materials and Methods: The study was conducted on female F1(CBA×C57Bl/6j) F1(CBAЧC57Bl/6j) mice with Ehrlich carcinoma transplanted into the right hind limb. The compound was administered intraperitoneally at a dose of 30 mg/kg on the day of irradiation and 48 hours after the first injection. The experimental methods included toxicometric and morphometric analyses. Results and Discussion: The median lethal dose of the compound was determined for intraperitoneal administration to mice, LD 50 = 60 mg/kg. Double injections in the monotherapy mode caused stable inhibition of tumor growth, which developed to 30 %. The combined use of radiation exposure and the studied compound led to significant increasing of therapeutic efficacy indicating the presence of synergistic interaction: the tumor growth inhibition index increased by 19 % with single electron irradiation, by 32 % with fractionated electron irradiation, and by 27 % with single proton irradiation. In addition, the experimental combination therapy, along with significant suppression of tumor growth, increased the survival of tumor-bearing animals without causing significant toxic effects. Conclusion: The obtained results indicate the prospects for further study of combined regimens of radiation therapy and indole-3-carbinol derivatives. Further studies of the mechanisms of interaction of these compounds and ionizing radiation should include an assessment of the effect on the main pathophysiological mechanisms of neoplasia development, key pathways of DNA repair and apoptosis.